Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996, 46: 907-911. 10.1212/WNL.46.4.907.
Article
CAS
PubMed
Google Scholar
Confavreux C, Vukusic S, Moreau T, Adeleine P: Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000, 343: 1430-1438. 10.1056/NEJM200011163432001.
Article
CAS
PubMed
Google Scholar
Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi MMX, De Sa J: Primary progressive multiple sclerosis. Brain. 1997, 120 (Pt 6): 1085-1096.
Article
PubMed
Google Scholar
Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N, Borge L, Hajem B, Lermet A, Sippl W, et al: Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One. 2009, 4: e7258-10.1371/journal.pone.0007258.
Article
PubMed
PubMed Central
Google Scholar
Humbert M, de Blay F, Garcia G, Prud'homme A, Leroyer C, Magnan A, Tunon-de-Lara JM, Pison C, Aubier M, Charpin D, et al: Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy. 2009, 64: 1194-1201. 10.1111/j.1398-9995.2009.02122.x.
Article
CAS
PubMed
Google Scholar
Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palmerini F, Mansfield CD, et al: Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol. 2010, 85: 921-925. 10.1002/ajh.21894.
Article
CAS
PubMed
Google Scholar
Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, Marquis C, Mely J, Hugonot-Diener L, Kinet JP, et al: Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther. 2011, 3: 16-10.1186/alzrt75.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tebib J, Mariette X, Bourgeois P, Flipo RM, Gaudin P, Le Loet X, Gineste P, Guy L, Mansfield CD, Moussy A, et al: Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther. 2009, 11: R95-10.1186/ar2740.
Article
PubMed
PubMed Central
Google Scholar
Nautiyal KM, Ribeiro AC, Pfaff DW, Silver R: Brain mast cells link the immune system to anxiety-like behavior. Proc Natl Acad Sci U S A. 2008, 105: 18053-18057. 10.1073/pnas.0809479105.
Article
CAS
PubMed
PubMed Central
Google Scholar
Silverman AJ, Sutherland AK, Wilhelm M, Silver R: Mast cells migrate from blood to brain. J Neurosci. 2000, 20: 401-408.
CAS
PubMed
Google Scholar
Theoharides TC, Cochrane DE: Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol. 2004, 146: 1-12. 10.1016/j.jneuroim.2003.10.041.
Article
CAS
PubMed
Google Scholar
Bradl M, Lassmann H: Progressive multiple sclerosis. Semin Immunopathol. 2009, 31: 455-465. 10.1007/s00281-009-0182-3.
Article
CAS
PubMed
Google Scholar
Brown MA, Tanzola MB, Robbie-Ryan M: Mechanisms underlying mast cell influence on EAE disease course. Mol Immunol. 2002, 38: 1373-1378. 10.1016/S0161-5890(02)00091-3.
Article
CAS
PubMed
Google Scholar
Theoharides TC, Kempuraj D, Kourelis T, Manola A: Human mast cells stimulate activated T cells: implications for multiple sclerosis. Ann N Y Acad Sci. 2008, 1144: 74-82. 10.1196/annals.1418.029.
Article
CAS
PubMed
Google Scholar
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001, 50: 121-127. 10.1002/ana.1032.
Article
CAS
PubMed
Google Scholar
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005, 58: 840-846. 10.1002/ana.20703.
Article
PubMed
Google Scholar
Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983, 33: 1444-1452. 10.1212/WNL.33.11.1444.
Article
CAS
PubMed
Google Scholar
Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, et al: Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999, 122 (Pt 5): 871-882.
Article
PubMed
Google Scholar
Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G: Administration and scoring manual for the multiple sclerosis functional composite meaure (MSFC). 1999, Demos, New York
Google Scholar
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N Engl J Med. 2000, 343: 938-952. 10.1056/NEJM200009283431307.
Article
CAS
PubMed
Google Scholar
Bebo BF, Yong T, Orr EL, Linthicum DS: Hypothesis: a possible role for mast cells and their inflammatory mediators in the pathogenesis of autoimmune encephalomyelitis. J Neurosci Res. 1996, 45: 340-348. 10.1002/(SICI)1097-4547(19960815)45:4<340::AID-JNR3>3.0.CO;2-9.
Article
CAS
PubMed
Google Scholar
Brenner T, Soffer D, Shalit M, Levi-Schaffer F: Mast cells in experimental allergic encephalomyelitis: characterization, distribution in the CNS and in vitro activation by myelin basic protein and neuropeptides. J Neurol Sci. 1994, 122: 210-213. 10.1016/0022-510X(94)90300-X.
Article
CAS
PubMed
Google Scholar
Kinet JP: The essential role of mast cells in orchestrating inflammation. Immunol Rev. 2007, 217: 5-7. 10.1111/j.1600-065X.2007.00528.x.
Article
CAS
PubMed
Google Scholar
Esposito P, Chandler N, Kandere K, Basu S, Jacobson S, Connolly R, Tutor D, Theoharides TC: Corticotropin-releasing hormone and brain mast cells regulate blood–brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther. 2002, 303: 1061-1066. 10.1124/jpet.102.038497.
Article
CAS
PubMed
Google Scholar
Letourneau R, Rozniecki JJ, Dimitriadou V, Theoharides TC: Ultrastructural evidence of brain mast cell activation without degranulation in monkey experimental allergic encephalomyelitis. J Neuroimmunol. 2003, 145: 18-26. 10.1016/j.jneuroim.2003.09.004.
Article
CAS
PubMed
Google Scholar
Skaper SD, Facci L, Romanello S, Leon A: Mast cell activation causes delayed neurodegeneration in mixed hippocampal cultures via the nitric oxide pathway. J Neurochem. 1996, 66: 1157-1166.
Article
CAS
PubMed
Google Scholar
Encinas JM, Manganas L, Enikolopov G: Nitric oxide and multiple sclerosis. Curr Neurol Neurosci Rep. 2005, 5: 232-238. 10.1007/s11910-005-0051-y.
Article
CAS
PubMed
Google Scholar
Rejdak K, Eikelenboom MJ, Petzold A, Thompson EJ, Stelmasiak Z, Lazeron RH, Barkhof F, Polman CH, Uitdehaag BM, Giovannoni G: CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis. Neurology. 2004, 63: 1439-1445. 10.1212/01.WNL.0000142043.32578.5D.
Article
CAS
PubMed
Google Scholar
Bidri M, Feger F, Varadaradjalou S, Ben Hamouda N, Guillosson JJ, Arock M: Mast cells as a source and target for nitric oxide. Int Immunopharmacol. 2001, 1: 1543-1558. 10.1016/S1567-5769(01)00097-2.
Article
CAS
PubMed
Google Scholar
Chu CL, Lowell CA: The Lyn tyrosine kinase differentially regulates dendritic cell generation and maturation. J Immunol. 2005, 175: 2880-2889.
Article
CAS
PubMed
Google Scholar
Krishnamoorthy N, Oriss TB, Paglia M, Fei M, Yarlagadda M, Vanhaesebroeck B, Ray A, Ray P: Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med. 2008, 14: 565-573. 10.1038/nm1766.
Article
CAS
PubMed
PubMed Central
Google Scholar
The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2: Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011, 476: 214-219. 10.1038/nature10251.
Article
Google Scholar